Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination

PR Newswire2021-08-13

- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Kritz_C
2021-08-13
Kritz_C
好
- Adrian88:
  Ok
- SimonChan:
  👍🏻
一初心一
2021-08-13
一初心一
Please like, thanks
- 2a3734f4:
  Sure
- Chitz:
  good
- Abcdefgg:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2159292105?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-13 20:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2159292105","market":"us","top_or_hot":-1,"title":"Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination","media":"PR Newswire","content":"<div>\n<p>- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity ...</p>\n\n<a href=\"https://finance.yahoo.com/news/memic-innovative-surgery-ltd-medtech-120700004.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMemic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 20:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/memic-innovative-surgery-ltd-medtech-120700004.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity ...</p>\n\n<a href=\"https://finance.yahoo.com/news/memic-innovative-surgery-ltd-medtech-120700004.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/memic-innovative-surgery-ltd-medtech-120700004.html","article_id":"2159292105","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/memic-innovative-surgery-ltd-medtech-120700004.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2159292105","pubTimestamp":1628857320,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniat","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Memic创新手术有限公司和MedTech收购公司宣布拟议的业务合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTAC":0.9,"MTACU":0.9,"MTACW":0.6},"content_text":"- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity and 360-degree articulation\n- Hominis' small, compact, and mobile design occupies a minimal footprint at a significant cost advantage compared to available robotic technology\n- The first FDA-authorized indication of Hominis is in women's health, including benign hysterectomy via the transvaginal approach, which is known to offer less pain, lower infection rates, faster recovery, and no visible scarring\n- The MedTech Acquisition Corporation management team and board of directors bring decades of medical device and surgical robotics commercialization experience\n- The combined companies are valued at an estimated pro-forma equity value of more than $1 billion, assuming no redemptions by MedTech's public stockholders\n- The Company will have approximately $360 million in pro forma cash on the balance sheet, assuming no redemptions by public stockholders of MedTech, less transactional expenses and operational expenses through closing, to support ongoing commercialization in women's healthcare and development of additional Hominis robot-assisted surgical applications\n- The business combination is supported by a $76 million PIPE with participation from leading investors, including Bridger Healthcare, Ltd., The Kraft Group, Monashee Investment Management LLC, Pura Vida Investments, Wellington Management, Ken Langone, Peregrine Ventures, HighSage Ventures, and management and board members of MedTech\nTEL AVIV, Israel and FORT LAUDERDALE, Fla., Aug. 13, 2021 /PRNewswire/ -- Memic Innovative Surgery Ltd. (the \"Company\" or \"Memic\"), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, and MedTech Acquisition Corporation (Nasdaq: MTAC) (\"MedTech\"), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, including surgical robotics, today announced that they have entered into a definitive agreement for a business combination. Upon the closing of the transaction, the combined company will operate under the Memic name and Maurice R. Ferré, MD, an independent director of MedTech and current Chairman of the board of Memic, will become Executive Chairman of the combined company. Memic will apply to have its ordinary shares listed on The Nasdaq Stock Market (\"Nasdaq\"). The business combination is expected to be completed in the fourth quarter of 2021.\n\"We are pleased to reach a merger agreement with MedTech, which represents a significant opportunity to advance the robot-assisted surgery market in ways that, until now, have been unattainable,\" said Dvir Cohen, co-founder and Chief Executive Officer of Memic. \"We believe the Hominis platform has the potential to transform the way surgeons perform robot-assisted procedures, beginning with our currently FDA-authorized indications that include transvaginal benign hysterectomy. Our partnership with the MedTech team, which provides decades of collective experience in surgical robotics, is an important step in bringing our advanced technology to medical facilities and patients across the United States and the world. We look forward to entering the public markets and working together with MedTech in the next phase of our company's journey.\"\n\"This agreement with Memic reflects the continued commitment of our management team and board of directors to deliver value to our stockholders,\" said Chris Dewey, Chief Executive Officer of MedTech. \"Following a comprehensive review of investment opportunities, we were impressed with the highly accomplished management team at Memic and its disruptive, minimally invasive, cost-effective Hominis system, which positions the Company well for substantial growth and profitability. We believe that Memic's innovative technology, coupled with our team's expertise in successfully commercializing medical device companies, has the potential to create significant value for stockholders in the years ahead.\"\n\"We believe that the Hominis platform represents the most significant advancement in soft-tissue surgical robotics in recent decades and this agreement further validates how our technology is positioned to transform the surgical robotics sector,\" said Maurice R. Ferré, MD, Co-founder of MAKO Surgical, Inc. \"Hominis is able to perform robotic transvaginal techniques that were previously unfeasible, fulfilling a significant unmet need in women's health, and we believe it has the potential to be applied to a broad range of indications in the future including general surgery.\"\nCompany Overview\nHominis received de novo marketing authorization from the FDA in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures, including benign hysterectomy. It is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation, allowing it to reach the entire surgical site. The Company's initial target addressable market is over 1 million women's health procedures in the United States and over 4 million globally. The Company plans to expand within women's health, as well as into additional applications including general, colorectal, thoracic, transoral and transrectal surgeries.\nThe biomimetic instruments are designed to replicate the motions and capabilities of a surgeon's arms, with shoulder, elbow, and wrist joints. Multiple instruments can be introduced into the body through a single portal and the 360-degree articulation offers the ability to bend and work around anatomic barriers, as well as optimal access and working angles. The system's proprietary instruments and human-like features enable surgeons to perform indicated gynecologic procedures using the transvaginal approach, which research shows results in better clinical outcomes for patients, including reduced pain, recovery time and rates of infection and no visible scarring.\nThe small, compact and mobile design of Hominis also offers a minimal footprint, with simple docking and a short setup time for surgeons, without requiring a dedicated operating room. Hominis can be purchased at a significant cost advantage compared to other available robotic technology.\nMemic has applied for a CE Mark for the Hominis system in additional countries outside the United States with decisions and expanded commercialization pending.\nAbout Memic\nMemic was founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary based in Fort Lauderdale, Florida, is a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology. For more information, visit: https://memicmed.com/.\nAbout MedTech Acquisition Corporation\nMedTech Acquisition Corporation (Nasdaq: MTAC) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":894785744,"gmtCreate":1628857664088,"gmtModify":1633688975766,"author":{"id":"4091502498282150","authorId":"4091502498282150","name":"Kritz_C","avatar":"https://static.tigerbbs.com/4438e1797b9d37c870aac4b550893d60","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"好","listText":"好","text":"好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894785744","repostId":2159292105,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5517770,"gmtCreate":1628859008213,"gmtModify":1635152423051,"authorId":4089878444731060,"author":{"id":4089878444731060,"authorId":4089878444731060,"name":"Adrian88","avatar":"https://static.tigerbbs.com/e6c821844139b158ef20aa398c55abd1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894785744,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5517934,"gmtCreate":1628859922446,"gmtModify":1635152411748,"authorId":3572212448091017,"author":{"id":3572212448091017,"authorId":3572212448091017,"name":"SimonChan","avatar":"https://static.tigerbbs.com/9becd538a97d2ba19c33053c87e741cf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894785744,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"}],"langContent":"CN"},{"id":894782536,"gmtCreate":1628857591225,"gmtModify":1633688976464,"author":{"id":"3579259159683278","authorId":"3579259159683278","name":"一初心一","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Please like, thanks","listText":"Please like, thanks","text":"Please like, thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/894782536","repostId":2159292105,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5517692,"gmtCreate":1628858535612,"gmtModify":1635152428001,"authorId":3584420866475715,"author":{"id":3584420866475715,"authorId":3584420866475715,"name":"2a3734f4","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894782536,"type":1,"supId":0,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"},{"id":5518552,"gmtCreate":1628862515529,"gmtModify":1635152371596,"authorId":3574934277926519,"author":{"id":3574934277926519,"authorId":3574934277926519,"name":"Chitz","avatar":"https://static.tigerbbs.com/988984eee397d7e772b978815d9b162e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894782536,"type":1,"supId":5517692,"prevId":0,"content":"<u>good</u>","text":"<u>good</u>","html":"<u>good</u>"},{"id":5518728,"gmtCreate":1628863228946,"gmtModify":1635152361783,"authorId":3574299068791767,"author":{"id":3574299068791767,"authorId":3574299068791767,"name":"Abcdefgg","avatar":"https://static.tigerbbs.com/91d18f2f3fa7070967448fd5432a6af3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894782536,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":43,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2159292105"}